NCT06994143View on ClinicalTrials.gov

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Rheumatoid Arthritis (RA
Interventions
DRUG

CLN-978

Specified dose on specified days

Trial Locations (2)

Unknown

RECRUITING

Cullinan Investigative Site, Erlangen

RECRUITING

Cullinan Investigative Site, Rome

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY

NCT06994143 - A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter